A Missing Gut Bacterium May Be Behind Your Fatty Liver Risk

If you have been told you have a fatty liver and no one can quite explain why, part of the answer may be missing from your gut. A new study published in the journal Gut Microbes traces a specific decline in one obscure gut bacterium, and the molecule it produces, to the fat buildup inside liver cells that defines metabolic dysfunction-associated steatotic liver disease (MASLD, the condition once called nonalcoholic fatty liver disease). The researchers did not stop at spotting a pattern in patients. They went on to prove, in mice, that restoring the bacterium's signature metabolite reverses the damage by switching off the exact protein that lets liver cells soak up fat.

Key takeaways

• A gut bacterium called Bacteroides cellulosilyticus is depleted in people with fatty liver disease, and its metabolite 2HPAA falls further as disease severity increases.
• In mice, supplementing either the bacterium or its metabolite reduced liver fat, body weight gain, and insulin resistance, by blocking a protein (PPARγ) that lets liver cells pull in fat.
• Researchers proved cause and effect in mice using a genetic knockout, but the human data is an association, not proof this works the same way in people.
• Nothing here is an approved treatment; no probiotic or supplement based on this bacterium has been tested in a human trial.

Bacteroides Cellulosilyticus and Its Metabolite 2HPAA Drive the Effect

A gut bacterium called Bacteroides cellulosilyticus (a fiber-fermenting microbe common in the human gut) and a small molecule it produces, 2-hydroxyphenylacetic acid (2HPAA, a byproduct formed when gut bacteria break down the amino acid phenylalanine), are the two factors this study ties most directly to protecting the liver from fat accumulation in MASLD. Researchers first screened a large public dataset of gut bacteria and found B. cellulosilyticus was consistently reduced in people carrying excess weight, and its abundance correlated with better cholesterol and liver enzyme readings. They then confirmed the same shortfall in two separate patient cohorts with fatty liver disease, cirrhosis, and type 2 diabetes. Follow-up metabolomics work, chemical profiling of what is circulating in feces, blood, and liver tissue, singled out 2HPAA as the specific molecule responsible for the bacterium's protective signal.

Fatty Liver Disease Affects a Huge Share of Adults, With No Approved Drug Yet

MASLD has become the most common chronic liver disease worldwide, and the researchers behind this study cite estimates of up to 38% of adults affected globally. Other reviews put the figure closer to 30%, with prevalence climbing from roughly 22% to 37% of adults between 1991 and 2019. The disease commonly travels alongside insulin resistance, type 2 diabetes, and cardiovascular disease, and it can progress silently from simple fatty buildup to inflammation, scarring (fibrosis), and in the most severe cases liver cancer. Despite how common it is, no drug has yet been approved anywhere in the world specifically to treat it, which is why researchers are increasingly looking at the gut-liver axis, the network of signals that gut bacteria and their byproducts send to the liver, for new leads.

A Large Human Cohort and a Genetic Knockout Proved the Chain of Cause and Effect

The study combined a very large observational dataset with tightly controlled lab experiments. The discovery phase drew on 2,800 adults from public metagenomic data, split into 1,631 people at a healthy weight and 1,169 who were overweight, to first flag B. cellulosilyticus as a bacterium of interest. To test whether the bacterium actually causes the effect rather than just tracking alongside it, the researchers fed mice a high-fat diet and gave some of them the bacterium (strain AF17-25, originally isolated from a healthy human donor) by mouth for eight weeks; those mice gained less weight, built up less fat in the liver, and had better blood sugar control than untreated mice, without eating less food. They then isolated 2HPAA as the active ingredient and showed that giving mice purified 2HPAA alone (at a dose of 150 mg/kg) reproduced the same protection. The strongest evidence came from a genetic knockout: when researchers disabled the bacterial gene (aroB) needed to manufacture 2HPAA's chemical precursor, the bacterium lost its protective effect in mice entirely, and supplementing those same mice with 2HPAA directly restored it. That knockout-and-rescue design is about as close as animal research gets to proving a specific molecule, not just the bacterium in general, is doing the work. Finally, the team validated the human relevance of 2HPAA in a separate cohort of 85 people (26 healthy, 29 with mild MASLD, 30 with moderate to severe MASLD), where blood levels of 2HPAA fell in step with worsening disease.

The Liver Mechanism: Blocking a Protein That Lets Cells Absorb Fat

Using single-cell sequencing of liver tissue, the researchers found that 2HPAA specifically shuts down a protein called PPARγ (peroxisome proliferator-activated receptor gamma, a regulator that controls which genes liver cells switch on for fat handling) in the zone of the liver most associated with fat synthesis. Turning down PPARγ, in turn, reduces a fat transporter called CD36, the protein that lets liver cells pull fatty acids in from the bloodstream, both by lowering how much CD36 the cell makes and by blocking a chemical modification CD36 needs to sit properly in the cell membrane and function. With less working CD36 on hand, liver cells absorb less fat from circulation. To confirm PPARγ was the real target rather than a side effect, the researchers gave mice a drug called Rosiglitazone, which activates PPARγ, alongside 2HPAA, and it reversed 2HPAA's benefits, reinforcing that this specific protein pathway is what's doing the work.

What This Could Mean If You're Managing Fatty Liver Risk

For someone already worried about fatty liver disease, insulin resistance, or related metabolic conditions, this study is a reason to pay attention to gut health research in this space, not a reason to go looking for a 2HPAA supplement or a B. cellulosilyticus probiotic. Neither exists as a tested product, and nothing in this study establishes that taking one would help a person the way it helped mice. What is worth discussing with a doctor, if you already have a MASLD diagnosis or risk factors like obesity or type 2 diabetes, is the broader point the study reinforces: gut bacteria composition and fiber-fermentation capacity appear connected to liver fat handling, which is one more reason diet and gut health are reasonable topics to raise alongside standard liver disease management.

What Remains Unproven: Human Data Is Still Correlational

The researchers themselves are explicit about the limits of their findings. The human cohort data, the drop in B. cellulosilyticus and 2HPAA seen in people with fatty liver disease, cirrhosis, and diabetes, is an association. It shows these levels move together with disease severity; it does not prove low 2HPAA causes disease in people, only that the causal chain was demonstrated in mice. A second loose end: a gene (hppD) previously reported as necessary for making 2HPAA was not found in this bacterium's own genome, meaning part of how B. cellulosilyticus actually produces the molecule is still not fully worked out. Finally, the large discovery cohort came from public datasets that lacked detailed clinical and dietary metadata, so the researchers could not account for participants' actual diets or confirm liver damage by biopsy in that initial group.

What Comes Next for This Gut-Liver Mechanism

The researchers call for future studies using biopsy-confirmed MASLD patients with detailed dietary tracking, to nail down whether restoring B. cellulosilyticus or supplementing 2HPAA could work as an actual treatment in people, not just a mouse model. They also note that boosting a protective bacterium like this one is only half of a two-sided strategy; other recent research has linked overgrowth of different gut bacteria to worsening fatty liver disease, and the authors suggest future treatments may need to pair restoring beneficial microbes with suppressing harmful ones. No timeline for human trials of 2HPAA itself was given.

Common Questions

Is Bacteroides cellulosilyticus the same as probiotics sold in stores? No. It is not currently available as a commercial probiotic, and this study did not test any store-bought supplement.

Does this mean low-fiber diets cause fatty liver disease? The study did not test diet directly in humans, since the discovery cohort lacked dietary data. It does show that a fiber-fermenting bacterium and its metabolite are linked to liver fat regulation, which fits a broader pattern connecting fiber intake to gut bacteria that support metabolic health, but this specific study cannot confirm a direct diet-to-disease link on its own.

Could a blood test for 2HPAA diagnose fatty liver disease? Not yet. The researchers describe 2HPAA as a candidate marker worth further study, but they are explicit that it has not been validated as a diagnostic tool and would need standardized thresholds tested in larger, independent patient groups first.

What does PPARγ have to do with fatty liver disease? PPARγ is a protein that normally helps liver cells switch on genes for taking in and storing fat. This study found that turning PPARγ down, which 2HPAA does, reduces how much fat liver cells absorb, making it a plausible drug target beyond this specific gut bacterium.

References

1. Kaiwei Chen, Zizhen Yang, Jixing Peng, et al. (2026). Bacteroides cellulosilyticus -derived 2-hydroxyphenylacetic acid rectifies hepatic lipid homeostasis in MASLD by targeting the PPARγ-CD36 axis. Gut Microbes. https://doi.org/10.1080/19490976.2026.2725392
2. Ha Vu (2025). Metabolic dysfunction-associated steatotic liver disease – masld. Tạp chí Khoa học tiêu hóa Việt Nam. https://doi.org/10.63583/cq45me13
3. Mykhailo Buchynskyi, Iryna Kamyshna, Iryna Halabitska, et al. (2025). Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2025.1577724